Pharmacology of Peripheral Neual Transmission Flashcards
Tetanus Toxin
Binds to synaptobrevin (V-SNARE), preventing vesicular NT release. Doesn’t act directly on the motor neuron, instead is retrogradely transported to the cell body, then transfers to inhibitory interneuron, which is unable to release NT and inhibit the motor neuron, which becomes more excitable as a result. Results in characteristic tetanus posture
Hemicholinium
Choline Co-Transporter Blocker. Prevents ACh synthesis by blocking the Na+ dependent choline co-transporter (SLC5A7).
Triethylcholine.
Competitive substrate that is acetylated to acetyltriethylcholone and released in place of ACh.
Vesamicol
Non Competitive Reversible ACh transporter blocker. Prevents newly synthesized ACh being loaded into storage vesicles by blocking vesicular ACh Transporter (VAChT)
Botulinum
Blocks ACh release. Exotoxin that enzymatically cleaves proteins required for ACh vesicle docking.
Beta-Bungarotoxin
Blocks ACh release. Has 2 functional chains that are linked by a S-S bond. 1 chain acts through phospholipase A2 activity, which is localised to the membrane through the K+ channel binding moiety found in the other chain. ? Apparently decreases release in the short term but then increases it long term?
Alpha-Latrotoxin
Causes massive ACh release. Tetramers form a Ca2+ permeable membrane pore. Also targets neurexins, latrophilin receptors (GPCRs) and other transmembrane proteins. Inhibits K+ channels and may lead to repiratory failure.
Alpha-Bungarotoxin
Irreversible NAChR blocker at the nmj. Does not affect (α3)2(β4)3 type (ganglionic) or (α4)2(β2)3 type (brain). It will block (α1)2β1δε type at the nmj and (α7)5 type also in the brain.
Trimetaphan
Competitive Anatagonist for ganglionic NAChRs, the (α3)2(β4)3 type. It is not active at the nmj, selective for the ganglionic isotope only.
Nicotine
NAChR agonist with a higher potency at the ganglion than the nmj. When “painted” on, causes stimulation then block of the ganglion (depolarising block with two phases)
Mecamylamine
Non-competitive NAChR antagonist- acts through channel blocking.
Hexamethonium
Use-dependent NAChR channel pore blocker: non-competitive antagonist. First drug to be used clinically for hypertension, but complicated effects due to action on ANS- the hexamethonium man.Changing chain length affects selectivity between ganglion and nmj, 6C methylene chain is the optimum length for ganglionic block.
D-Tubocurarine
Competitive antagonist of NAChR, causing a non-depolarising block. Relatively non-selective between the nmj and the ganglion at clinical doses, however 70-80% occupancy must be achieved to result in transmission failure.
Pancuronium
Competitive antagonist of the NAChR at the nmj. As a quaternary ammonium compound it is not orally active. It blocks the EPP in response to nerve stimulation and directly application of ACh externally.it is used for longer operations as it is not easily hydrolysed, so has a sustained effect.
Atracurium
Competitive antagonist of the NAChR at the nmj. As a quaternary ammonium compound it is not orally active. It blocks the EPP in response to nerve stimulation and directly application of ACh externally. It is an ester that is broken down by spontaneous hydrolysis so it has a short lives effect in most patients.
Decamethonium and Suxamethonium
Depolarising neuromuscular blocking agent, selective for NAChRs at the nmj. They block transmission by causing a prolonged depolarization. During phase 1, their effects are potentiated by anti-ChEs and countered by non-depolarising blockers. In phase 2, anti-ChEs reverse the blockade. Suxamethonium is in clinical use do very short procedures (e.g. Intubation) as normally it is rapidly broken down NB- in 0.1-0.2% of the population they have a deficiency in enzyme activity which can prolong its action.
ACh and Carbachol
Non-selective agonists of the AChR, acting on both nicotinic and muscarinic types
Muscarine
Selective MAChR agonist
Methacholine
Non-selective AChR agonist that has two isomers. Neither can be broken down by BuChE but (+) Methacholine can bee hydrolysed by AChE and is 200x more potent than the (-) isomer at the MAChR.
Bethanechol
Non-selective muscarinic AChR agonist, poorly absorbed from the GI tract and it’s polar nature means it is rapidly excreted from the kidneys, so of limited clinical use. Used systematically to treat bladder dysfunction.
Pilocarpine
Also a non-selective MAChR that is poorly absorbed from the GI Tract. Used in the treatment of glaucoma- ciliary muscle contraction produces traction in trabecular meshwork that facilitates the drainage of aqueous humour.
Cevimeline
M3 selective agonist that can increase salivation and lacrimal ion in conditions such as Sjögren’s syndrome- an autoimmune disease of fluid secreting glands.
Atropine
Non-selective MAChR antagonist used to produce pupillary dilation- however long duration of action makes adrenoreceptor agonists more suitable
Benzilylcholine Mustard
Non-selective irreversible MAChR antagonist.
Pirenzipine
Selective M1 antagonist, acting on receptors of intramural nerves in local ganglia rather than the oxytocin cells themselves. Used as an antosecretory agent in the treatment of gastroduodenal ulcers.
Darifenacin
Selective M3AChR antagonist used to mediate bladder contraction in the treatment of incontinence.
Edrophonium
Non-covalent, truly reversible inhibitor of AChE. Quaternary ammonium compound that binds only to the ionic site of the enzyme through electrostatic interactions. A useful diagnostic of myasthenia gravis- it’s effects last only a few minutes, causing a temporary increase in the muscle tension that can be acheived by an affected patient
Neostigmine
Moderately reversible inhibitor that binds to the ester of site (present on BuChE and AChE) via a weak covalent interaction. The cholinesterase is inhibited for several minutes. Used intravenously to reverse neuromuscular blockade after surgery, also taken orally as a treatment for myesthenia gravis
Sugammadex
Cyclic dextrin that forms an inactive complex in the plasma with steroidal nmj blocking drugs which can be excreted in the kidneys, thus relieving the block
Dyflos
Irreversible ACh inhibitor. An organophosphorus compound that can produce a strong covalent bond between the phosphorus atom and serine residue at the esteric site. Used in the treatment of glaucoma.